US 9,809,634 B2
Composition comprising branched multipeptide vaccine and vaccine comprising the same
Tae-Young Jung, Gwangju (KR); and Young-Hee Kim, Gwangju (KR)
Assigned to INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY, Gwangju (KR)
Filed by INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY, Gwangju (KR)
Filed on Dec. 31, 2015, as Appl. No. 14/985,660.
Claims priority of application No. 10-2015-0109936 (KR), filed on Aug. 4, 2015.
Prior Publication US 2017/0037154 A1, Feb. 9, 2017
Int. Cl. C07K 14/47 (2006.01); C07K 7/06 (2006.01); C07K 14/705 (2006.01); C07K 14/445 (2006.01); A61K 39/00 (2006.01)
CPC C07K 14/4747 (2013.01) [A61K 39/0011 (2013.01); C07K 7/06 (2013.01); C07K 14/445 (2013.01); C07K 14/4703 (2013.01); C07K 14/4748 (2013.01); C07K 14/70596 (2013.01); A61K 2039/627 (2013.01); A61K 2039/645 (2013.01); A61K 2039/70 (2013.01); C07K 2319/00 (2013.01)] 3 Claims
 
1. A multi-peptide composition for cancer immunotherapy, represented by Chemical Formula I below:

OG Complex Work Unit Drawing
in Chemical Formula I,
each of A, B and C is independently a subsequence residue of any one brain tumor antigen selected from the group consisting of: CD99, BIRC5, ERBB2, WT-1 and PanDR epitope;
Sp is a spacer that links the subsequence residue to lysine; and
Lys is lysine,
wherein A has any one amino acid sequence selected from SEQ ID NOs: 1 to 5, B has any one amino acid sequence selected from SEQ ID NOs: 6 to 9, and C has any one amino acid sequence selected from SEQ ID NOs: 10 to 13.